
|Articles|September 18, 2015
Sara M. Tolaney on Neoadjuvant Treatment Considerations for Triple-Negative Breast Cancer
Author(s)Sara M. Tolaney, MD, MPH
There are many clinical trial opportunities, Tolaney says, before surgery.
Advertisement
Sara M. Tolaney, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer.
“[There are] lots of potential clinical trial opportunities prior to surgery because we do have this question about whether or not platinum therapy is beneficial,” Tolaney says.
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Lynch Syndrome: Why Upper Endoscopies and Colonoscopy Prep Save My Life
2
Top 5 Takeaways From ASCO 2026 That Patients Should Know
3
Iza-Bren Improves Survival in Metastatic Triple-Negative Breast Cancer
4
FDA Approves Cavhanza for PH-positive Chronic Myeloid Leukemia
5




